Dr. Chablani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5150 Centre Ave
Pittsburgh, PA 15232Phone+1 412-648-6686
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 2016 - 2019
Ohio State University College of MedicineClass of 2016
Certifications & Licensure
PA State Medical License 2022 - 2024
IL State Medical License 2019 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.Priyanka V Chablani, Theodore Karrison, Walter M Stadler
Clinical Genitourinary Cancer. 2022-12-01 - 5 citationsBRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma.Adam R. Wolfe, Priyanka Chablani, Michael Siedow, Eric D. Miller, Steve Walston
Radiation Oncology. 2021-04-13 - 3 citationsDo Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management.Evan Wuthrick, Priyanka Chablani
Seminars in Radiation Oncology. 2019-04-01
Press Mentions
Large, Grade 4 Kidney Tumors Pose Risk of Early Cancer-Specific MortalityNovember 12th, 2024- Upfront TKI for Bone-Predominant RCC Tops Single-Agent ImmunotherapyNovember 12th, 2024
- Higher Risk of Kidney Cancer Recurrence After Ablative TherapyNovember 10th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
